---
id: nccn-diffuse-large-b-cell-lymphoma-2024
title: "NCCN 2024 Clinical Practice Guidelines: Diffuse Large B-Cell Lymphoma"
short_title: "NCCN DLBCL 2024"

organization: National Comprehensive Cancer Network
collaborators: null
country: US
url: https://www.nccn.org/guidelines/
doi: null
pmid: null
open_access: false

specialty: oncology
guideline_type: clinical-practice
evidence_system: NCCN
conditions:
  - diffuse large B-cell lymphoma
  - DLBCL
  - non-Hodgkin lymphoma
tags:
  - R-CHOP
  - CAR-T
  - polatuzumab
  - PET-CT
  - autologous transplant

publication_date: 2024-09-01
previous_version_date: 2023-08-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-26
---

## Scope
2024 NCCN clinical practice guideline on the diagnosis and treatment of diffuse large B-cell lymphoma (DLBCL).

## Key Recommendations

### Diagnosis
- Excisional biopsy preferred; core biopsy acceptable.
- Immunohistochemistry: CD20+, variable CD10, BCL6, BCL2, MUM1.
- Cell of origin (GCB vs. non-GCB/ABC) by IHC or gene expression.
- FISH for MYC, BCL2, BCL6 rearrangements (identify high-grade/double-hit lymphoma).

### Staging
- Lugano staging; Ann Arbor-based.
- PET-CT (baseline and response assessment).
- Bone marrow biopsy often replaced by PET if positive.

### First-Line Treatment

#### Limited Stage (I-II)
- **R-CHOP x 3-4 cycles Â± ISRT** OR **R-CHOP x 6 cycles**.

#### Advanced Stage (III-IV)
- **Pola-R-CHP x 6 cycles**: Polatuzumab vedotin + R-CHP (replacing vincristine). Preferred based on POLARIX trial (improved PFS).
- **R-CHOP x 6 cycles**: Standard alternative.

#### High-Risk (Double-Hit, Triple-Hit)
- **DA-EPOCH-R**: Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin + rituximab.

### Response Assessment
- Interim PET after 2-4 cycles may guide treatment.
- End-of-treatment PET (Deauville score).

### Relapsed/Refractory DLBCL
- **CAR-T Cell Therapy (Axi-cel, Liso-cel, Tisa-cel)**: Approved for relapsed/refractory DLBCL after 2+ lines (and now second-line for primary refractory or early relapse).
- **Salvage Chemotherapy + Auto-SCT**: For chemosensitive relapse.
- **Polatuzumab + BR, Loncastuximab, Tafasitamab + Lenalidomide, Glofitamab (bispecific), Epcoritamab**: Additional options.

### CNS Prophylaxis
- Consider for high CNS IPI risk.
